Bioequivalence study between two fluticasone propionate 500μg/salmeterol 50μg inhalation powders

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504789-48-00

Acronym

BECRO/RESP/AEROPK500

Enrollment

Registered

2023-07-13

Start date

2023-08-23

Completion date

2024-03-22

Last updated

2023-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteers: regular treatment of bronchial asthma, where a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist (LABA) is indicated for: •Twice-daily treatment of asthma in patients aged 4 years and older. •Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD).

Interventions

None listed

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Countries

Greece

Outcome results